Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Acelrx Pharmaceutica (ACRX)

Acelrx Pharmaceutica (ACRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 112,262
  • Shares Outstanding, K 80,764
  • Annual Sales, $ 2,290 K
  • Annual Income, $ -53,240 K
  • 60-Month Beta 1.84
  • Price/Sales 52.93
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -0.16
  • Number of Estimates 2
  • High Estimate -0.12
  • Low Estimate -0.19
  • Prior Year -0.16
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.3500 +2.96%
on 05/15/20
1.8200 -23.63%
on 04/30/20
-0.1900 (-12.03%)
since 04/29/20
3-Month
0.7014 +98.18%
on 03/23/20
1.8200 -23.63%
on 04/30/20
+0.0700 (+5.30%)
since 02/28/20
52-Week
0.7014 +98.18%
on 03/23/20
3.0200 -53.97%
on 07/10/19
-1.4400 (-50.88%)
since 05/29/19

Most Recent Stories

More News
Tetraphase Announces Second Amendment to Merger Agreement with AcelRx Pharmaceuticals for Increased Consideration

Tetraphase Pharmaceuticals, Inc. (Nasdaq:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVA(TM) (eravacycline for injection) to treat serious and life-threatening...

ACRX : 1.3900 (-7.33%)
TTPH : 2.16 (-4.42%)
AcelRx Pharmaceuticals Announces Revised Merger Agreement with Tetraphase

, /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (AcelRx) (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically...

ACRX : 1.3900 (-7.33%)
TTPH : 2.16 (-4.42%)
Tetraphase Announces Receipt of Amended Melinta Proposal, Determination of Superior Offer and Notice to AcelRx

Tetraphase Pharmaceuticals, Inc. (Nasdaq:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVA(TM) (eravacycline for injection) to treat serious and life-threatening...

ACRX : 1.3900 (-7.33%)
MLNT : 0.4400 (-12.00%)
TTPH : 2.16 (-4.42%)
AcelRx Pharmaceuticals Announces Revised Merger Agreement with Tetraphase

, /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (AcelRx) (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically...

ACRX : 1.3900 (-7.33%)
TTPH : 2.16 (-4.42%)
Tetraphase Announces Amendment to Merger Agreement with AcelRx Pharmaceuticals for Increased Consideration

Tetraphase Pharmaceuticals, Inc. (Nasdaq:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVA(TM) (eravacycline for injection) to treat serious and life-threatening...

ACRX : 1.3900 (-7.33%)
TTPH : 2.16 (-4.42%)
Tetraphase Announces Determination of Superior Offer and Notice to AcelRx

Tetraphase Pharmaceuticals, Inc. (Nasdaq:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline Xerava(TM) (eravacycline for injection) to treat serious and life-threatening...

ACRX : 1.3900 (-7.33%)
MLNT : 0.4400 (-12.00%)
TTPH : 2.16 (-4.42%)
AcelRx Pharmaceuticals (ACRX) Reports Q1 Loss, Misses Revenue Estimates

AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of -33.33% and -85.43%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?...

ACRX : 1.3900 (-7.33%)
AcelRx Pharmaceuticals Reports First Quarter 2020 Financial Results

, /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically...

ACRX : 1.3900 (-7.33%)
All You Need to Know About AcelRx Pharmaceuticals (ACRX) Rating Upgrade to Buy

AcelRx Pharmaceuticals (ACRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

ACRX : 1.3900 (-7.33%)
Is a Beat in Store for Sunoco (SUN) This Earnings Season?

Stable earnings from expansive fuel distribution assets are likely to have boosted Sunoco's (SUN) Q1 earnings.

SUN : 25.80 (+1.45%)
ALGT : 106.55 (+0.58%)
ACRX : 1.3900 (-7.33%)
ADPT : 38.70 (-0.57%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade ACRX with:

Business Summary

AcelRx Pharmaceuticals, Inc., is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of pain. The Company product candidates comprises: ARX-01 or the Sufentanil NanoTab PCA System; ARX-02 or the Sufentanil NanoTab BTP Management System; and...

See More

Key Turning Points

2nd Resistance Point 1.6100
1st Resistance Point 1.5000
Last Price 1.3900
1st Support Level 1.3200
2nd Support Level 1.2500

See More

52-Week High 3.0200
Fibonacci 61.8% 2.1343
Fibonacci 50% 1.8607
Fibonacci 38.2% 1.5871
Last Price 1.3900
52-Week Low 0.7014

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar